These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 29974604)

  • 1. Value of repeat radical transurethral resection for selected patients with muscle-invasive bladder cancer.
    Li Z; Li Y; Lu Q; Chen J
    ANZ J Surg; 2018 Oct; 88(10):1033-1036. PubMed ID: 29974604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
    Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of second transurethral resection on patient outcomes in muscle-invasive bladder cancer patients treated with bladder-preserving multimodal therapy.
    Suer E; Hamidi N; Gokce MI; Gulpinar O; Turkolmez K; Beduk Y; Baltaci S
    World J Urol; 2016 Jun; 34(6):847-51. PubMed ID: 26462931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
    May M; Helke C; Nitzke T; Vogler H; Hoschke B
    Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining DWI radiomics features with transurethral resection promotes the differentiation between muscle-invasive bladder cancer and non-muscle-invasive bladder cancer.
    Xu S; Yao Q; Liu G; Jin D; Chen H; Xu J; Li Z; Wu G
    Eur Radiol; 2020 Mar; 30(3):1804-1812. PubMed ID: 31773297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of time to second transurethral resection on oncological outcomes of patients with high-grade T1 bladder cancer treated with intravesical Bacillus Calmette-Guerin.
    Calò B; Falagario U; Sanguedolce F; Veccia A; Chirico M; Carvalho-Diaz E; Mota P; Lima E; Autorino R; Carrieri G; Cormio L
    World J Urol; 2020 Dec; 38(12):3161-3167. PubMed ID: 32062805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of a prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer.
    Rolevich AI; Zhegalik AG; Mokhort AA; Minich AA; Vasilevich VY; Polyakov SL; Krasny SA; Sukonko OG
    World J Urol; 2017 May; 35(5):745-752. PubMed ID: 27604374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving bacillus Calmette-Guérin.
    Angulo JC; Palou J; García-Tello A; de Fata FR; Rodríguez O; Villavicencio H
    Actas Urol Esp; 2014 Apr; 38(3):164-71. PubMed ID: 24613147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of a second transurethral resection for T1 bladder cancer.
    Schwaibold HE; Sivalingam S; May F; Hartung R
    BJU Int; 2006 Jun; 97(6):1199-201. PubMed ID: 16566814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radical transurethral resection and chemotherapy in the treatment of muscle-invasive bladder cancer: a long-term follow-up.
    Thomas DJ; Roberts JT; Hall RR; Reading J
    BJU Int; 1999 Mar; 83(4):432-7. PubMed ID: 10210567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome.
    Herr HW
    J Clin Oncol; 2001 Jan; 19(1):89-93. PubMed ID: 11134199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasive, high grade transitional cell carcinoma of the bladder treated with transurethral resection. A survival analysis focusing on TUR as monotherapy.
    Roosen JU; Geertsen U; Jahn H; Weinreich J; Nissen HM
    Scand J Urol Nephrol; 1997 Feb; 31(1):39-42. PubMed ID: 9060082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeat transurethral resection for non-muscle-invasive bladder cancer: a contemporary series.
    Gendy R; Delprado W; Brenner P; Brooks A; Coombes G; Cozzi P; Nash P; Patel MI
    BJU Int; 2016 Apr; 117 Suppl 4():54-9. PubMed ID: 26486968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bladder sparing surgery in high-grade bladder cancer.
    Yakovlev PG; Klyushin DA; Vereshchako RI
    Exp Oncol; 2019 Jun; 41(2):160-165. PubMed ID: 31262149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.
    Sternberg IA; Keren Paz GE; Chen LY; Herr HW; Dalbagni G
    BJU Int; 2013 Jul; 112(1):54-9. PubMed ID: 23146082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Radical cystectomy in the treatment of bladder cancer always in due time?].
    May M; Braun KP; Richter W; Helke C; Vogler H; Hoschke B; Siegsmund M
    Urologe A; 2007 Aug; 46(8):913-9. PubMed ID: 17676301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of surveillance in the treatment of patients with muscle-invasive bladder cancer after chemotherapy.
    Hellenthal NJ; Ramirez ML; Evans CP; Devere White RW
    BJU Int; 2010 Feb; 105(4):485-8. PubMed ID: 19849694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell carcinoma of the bladder.
    Serretta V; Piazza S; Pavone C; Piazza B; Pavone-Macaluso M
    Urology; 1996 May; 47(5):647-51. PubMed ID: 8650860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.